Trial Profile

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 3 Study of ITM-058 in Patients with Osteoporosis

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 24 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abaloparatide (Primary)
Indications Osteoporosis
Focus Registrational; Therapeutic Use
Acronyms ACTIVE-J
Sponsors Teijin Pharma

Most Recent Events

18 Mar 2026 According to Paratek Pharmaceuticals media release, Radius Health Inc. has been acquired and merged into Paratek Pharmaceuticals.
17 Aug 2022 Results published in the Journal of Clinical Endocrinology and Metabolism
09 Sep 2020 According to a Radius Health media release, Teijin Pharma Limited will be sharing detailed data from this study at the upcoming American Society for Bone and Mineral Research (ASBMR) 2020 Annual Virtual Meeting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com